Novavax 과거 순이익 실적
과거 기준 점검 0/6
Novavax은 연평균 49.9%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 33.8%의 비율로 증가했습니다. 매출은 연평균 7.7%의 비율로 감소했습니다.
핵심 정보
49.89%
순이익 성장률
53.82%
주당순이익(EPS) 성장률
| Biotechs 산업 성장률 | 17.04% |
| 매출 성장률 | -7.72% |
| 자기자본이익률 | n/a |
| 순이익률 | -14.73% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
Seeking Alpha • May 12
Novavax: Betting On This Vaccine Maker's Turnaround Story, After Pfizer Deal
Summary Novavax receives a Hold rating, reflecting neutral fundamentals despite a Q1 earnings beat and strong recent price momentum. NVAX's upside hinges on executing strategic partnerships, notably with Pfizer, and advancing its vaccine pipeline amid sector tailwinds from infectious disease outbreaks. Profitability remains elusive, with negative equity and choppy cash flow; consensus expects no positive EPS until at least 2028. Valuation implies nearly 40% upside to Wall Street's $14.11 target, but technicals and seasonal demand volatility temper conviction in a sustained rally. Read the full article on Seeking Alpha
내러티브 업데이트 • Apr 26
NVAX: Bearish View Will Hinge On Sustained COVID Vaccination Demand
Analysts have raised their blended price targets for Novavax by about $1 per share to a range of around $7 to $8, citing updated assumptions for COVID demand, refreshed 2026 revenue and expense forecasts, and the contribution from recent partnership agreements. Analyst Commentary Recent Street research around Novavax reflects a mix of caution and tempered expectations, even as price targets move slightly higher into the mid single digit range.내러티브 업데이트 • Apr 11
NVAX: Bearish View Will Hinge On Future COVID Demand Execution
Analysts have modestly lifted their average price targets on Novavax shares, with several moving from the $6 to $7 range toward $8 as they update COVID demand assumptions and incorporate new guidance on future revenue, operating expenses, and licensing income. Analyst Commentary Recent Street research on Novavax reflects a cautious tone, even as some targets edge higher.내러티브 업데이트 • Mar 28
NVAX: Bearish Outlook Will Depend On Pfizer Royalty And COVID Demand Assumptions
Novavax's average analyst price target has edged higher by about $1, as analysts refine their COVID assumptions, update revenue and expense forecasts for future years, and factor recent partnership economics into their models. Analyst Commentary Recent Street research around Novavax points to a cautious tone, even as price targets move slightly higher.내러티브 업데이트 • Mar 14
NVAX: Cautious Outlook Will Hinge On Future Pfizer Royalty Execution
Narrative Update on Novavax The analyst price target for Novavax has increased by about $1 to a new consensus of $7, as analysts adjust their models for updated COVID demand assumptions, refreshed 2026 revenue and expense forecasts, and the impact of recent partnership and licensing agreements. Analyst Commentary Recent Street research on Novavax points to a mixed but generally cautious stance.
내러티브 업데이트 • Feb 27
NVAX: Licensing And Royalty Streams Will Drive Future Cash Generation
Analysts have lifted their average price target on Novavax to about $13.78 from roughly $13.11, citing updated COVID demand assumptions, refreshed revenue and expense forecasts, and revised P/E expectations that incorporate recent guidance and licensing agreements. Analyst Commentary Recent Street research reflects a mix of cautious optimism and ongoing concern, with several firms adjusting their price targets and underlying models around Novavax's COVID franchise, expense profile, and licensing income.분석 기사 • Jan 14
Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 32% in the last...내러티브 업데이트 • Nov 08
NVAX: Shifting To Licensing Will Drive Royalties And Upfront Payments
Novavax's analyst price target has been modestly reduced from $13.21 to $13.11 per share. This change reflects analysts' cautious optimism about the company's new licensing model, expected royalties, and commercial partnership opportunities.내러티브 업데이트 • Oct 24
Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead
The analyst price target for Novavax has been raised from $12.50 to $13.21. This reflects analyst confidence in the company’s transition to a licensing model as well as opportunities for revenue from new partnerships and technology platforms.내러티브 업데이트 • Sep 04
Global Vaccine Market Will Unlock Upside Despite Execution Risks
Novavax’s consensus price target was modestly reduced, primarily due to a slight decline in its future P/E ratio, bringing fair value down from $12.86 to $12.50. What's in the News Reports indicate that the Trump administration and Robert F.분석 기사 • May 20
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 29% But Investors Aren't Buying For Growth
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 29% in the last...Seeking Alpha • Apr 28
Novavax: Grandiose Ambitions, Smart Strategy, But FDA Decision Adds To Challenges
Summary Novavax's recent performance shows improvement, but significant challenges persist, impacting long-term growth and stability. The company's financials have strengthened due to strategic moves, yet uncertainties in its COVID-19 vaccine remain. NVAX stock's rating maintained at "Hold" despite ongoing hurdles based on improved cash position and potential future opportunities. Investors should remain cautious, balancing optimism with awareness of persistent risks and market volatility. Read the full article on Seeking Alpha
새로운 내러티브 • Apr 22
Sanofi Partnership And Pipeline Programs Will Expand Future Markets
Strategic partnerships and new vaccine programs could significantly boost Novavax's future revenue and market expansion efforts.Seeking Alpha • Apr 11
Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer
Summary Novavax's $500M Sanofi partnership with a potential $700M in milestones provides stability as the company transitions to a partnership-focused strategy. Health Secretary Kennedy's claim that single-antigen vaccines don't work for respiratory diseases caused Novavax stock to plummet 20%. FDA approval delay for Nuvaxovid jeopardizes a crucial $175M milestone payment, though Novavax has the financial flexibility to survive this setback. Despite significant regulatory and competitive risks, NVAX stock maintains a "Hold" rating as a speculative component for barbell portfolios. Read the full article on Seeking Alpha분석 기사 • Apr 02
The Market Doesn't Like What It Sees From Novavax, Inc.'s (NASDAQ:NVAX) Revenues Yet As Shares Tumble 28%
Novavax, Inc. ( NASDAQ:NVAX ) shareholders that were waiting for something to happen have been dealt a blow with a 28...분석 기사 • Mar 12
Some Novavax, Inc. (NASDAQ:NVAX) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for Novavax, Inc. ( NASDAQ:NVAX ) shareholders, with the analysts delivering a substantial...Seeking Alpha • Jan 16
Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)
Summary I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of relative weakness. The partnership with Sanofi offers significant benefits but does not assure it of ongoing success. My analysis remains cautious, emphasizing the need for careful consideration of Novavax's long-term viability and strategic moves. Read the full article on Seeking Alpha분석 기사 • Dec 17
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 26% in the last...분석 기사 • Nov 15
Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target
Novavax, Inc. ( NASDAQ:NVAX ) defied analyst predictions to release its third-quarter results, which were ahead of...Seeking Alpha • Nov 13
Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway
Summary Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a substantial cost reduction program set to refocus the company on 4 key value drivers. A collaboration with Sanofi offers flexibility and potential growth, allowing Novavax to focus on developing a COVID-19/influenza combination (CIC) and seasonal influenza vaccines. Despite effective products, reduced guidance and restructuring uncertainty make NVAX stock a hold, with the Sanofi partnership and upcoming milestones as a potential bullish catalyst. Read the full article on Seeking Alpha분석 기사 • Nov 01
Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues
Novavax, Inc. ( NASDAQ:NVAX ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Oct 31
Novavax Q3 Earnings A Week Away - Time To Accept A New Reality
Summary Novavax' Q3 earnings are due on 6th November. The vaccine developer was part of Operation Warp Speed, receiving $1.8bn of funding from the US government to develop a COVID vaccine. Novavax succeeded, but Nuvaxovid came to the market too late to build market share and the company ended up making heavy losses. Sanofi has acquired the rights to nuvaxovid, paying Novavax $500m upfront, and will look to develop a COVID / Influenza combo vaccine using Novavax' technology. Unfortunately, Sanofi milestones and revenues aside, that leaves Novavax with few opportunities to generate revenue, which likely means its valuation will fall over time. Read the full article on Seeking AlphaSeeking Alpha • Sep 01
Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones
Summary Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.1 variant, but newer Omicron variants have outpaced it, limiting competitive advantage. Financial stability hinges on achieving key milestones in the Sanofi partnership and successful commercialization of new vaccines. Despite the Sanofi deal, maintaining a "hold" position is prudent given the high-risk nature of Novavax's future prospects. Read the full article on Seeking Alpha분석 기사 • Aug 14
Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business
Novavax, Inc.'s ( NASDAQ:NVAX ) price-to-sales (or "P/S") ratio of 2x might make it look like a strong buy right now...Seeking Alpha • Aug 13
Novavax: Staying Long Despite Coming Up Short In Q2
Summary Novavax reported Q2 earnings with a miss on EPS and revenue, causing a drop in share price, but recovered after the earnings call. Novavax is making progress with internal vaccine candidates, Sanofi partnership, and potential market opportunities, despite disappointing Q2 earnings. I provide my thoughts on the quarter, and will highlight a few downside risks that investors should consider. I discuss my updated NVAX strategy. Read the full article on Seeking AlphaSeeking Alpha • Jul 26
Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal
Summary Novavax's Q1 2024 earnings were so-so, but a major partnership with Sanofi sent its share price soaring by 200%. The Sanofi deal provides essential funding but restricts Novavax's future earning potential, making it reliant on revenue streams from Sanofi. Novavax's long-term prospects may be challenging as it may struggle to develop new products and could see its revenue streams dry up post-2025. In this review ahead of Q2 earnings (to be announced on August 6) I take a deeper look at the Sanofi deal, and what to expect from Q2 earnings. Read the full article on Seeking Alpha매출 및 비용 세부 내역
매출 및 비용 세부 내역
Novavax가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 596 | -88 | 127 | 0 |
| 31 Dec 25 | 1,123 | 440 | 150 | 0 |
| 30 Sep 25 | 1,065 | 342 | 195 | 0 |
| 30 Jun 25 | 1,079 | 423 | 230 | 0 |
| 31 Mar 25 | 1,255 | 479 | 302 | 0 |
| 31 Dec 24 | 682 | -187 | 324 | 0 |
| 30 Sep 24 | 885 | -285 | 444 | 41 |
| 30 Jun 24 | 988 | -294 | 437 | 41 |
| 31 Mar 24 | 997 | -399 | 427 | 41 |
| 31 Dec 23 | 984 | -545 | 457 | 0 |
| 30 Sep 23 | 1,050 | -549 | 464 | 0 |
| 30 Jun 23 | 1,597 | -587 | 513 | 0 |
| 31 Mar 23 | 1,359 | -1,155 | 505 | 0 |
| 31 Dec 22 | 1,982 | -658 | 489 | 67 |
| 30 Sep 22 | 1,847 | -1,322 | 411 | 0 |
| 30 Jun 22 | 1,291 | -1,476 | 366 | 0 |
| 31 Mar 22 | 1,403 | -1,318 | 331 | 0 |
| 31 Dec 21 | 1,146 | -1,744 | 298 | 0 |
| 30 Sep 21 | 1,204 | -1,075 | 273 | 0 |
| 30 Jun 21 | 1,182 | -950 | 252 | 0 |
| 31 Mar 21 | 919 | -615 | 196 | 0 |
| 31 Dec 20 | 476 | -418 | 143 | 0 |
| 30 Sep 20 | 205 | -273 | 92 | 0 |
| 30 Jun 20 | 50 | -93 | 43 | 0 |
| 31 Mar 20 | 18 | -115 | 35 | 0 |
| 31 Dec 19 | 19 | -133 | 34 | 0 |
| 30 Sep 19 | 16 | -150 | 35 | 0 |
| 30 Jun 19 | 21 | -177 | 36 | 0 |
| 31 Mar 19 | 29 | -182 | 34 | 0 |
| 31 Dec 18 | 34 | -185 | 34 | 0 |
| 30 Sep 18 | 39 | -186 | 34 | 0 |
| 30 Jun 18 | 39 | -186 | 34 | 0 |
| 31 Mar 18 | 35 | -186 | 34 | 0 |
| 31 Dec 17 | 31 | -184 | 34 | 0 |
| 30 Sep 17 | 26 | -190 | 34 | 0 |
| 30 Jun 17 | 21 | -212 | 40 | 0 |
| 31 Mar 17 | 17 | -247 | 45 | 0 |
| 31 Dec 16 | 15 | -280 | 47 | 0 |
| 30 Sep 16 | 16 | -302 | 47 | 0 |
| 30 Jun 16 | 19 | -269 | 43 | 0 |
| 31 Mar 16 | 31 | -210 | 36 | 0 |
| 31 Dec 15 | 36 | -157 | 31 | 0 |
| 30 Sep 15 | 37 | -110 | 27 | 0 |
| 30 Jun 15 | 39 | -96 | 23 | 0 |
양질의 수익: NVAX 은(는) 현재 수익성이 없습니다.
이익 마진 증가: NVAX는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: NVAX는 수익성이 없지만 지난 5년 동안 연평균 49.9%의 속도로 손실을 줄였습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 NVAX의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: NVAX은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: NVAX의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 06:02 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Novavax, Inc.는 24명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Alec Stranahan | BofA Global Research |
| David Lebowitz | Brean Capital Historical (Janney Montgomery) |
| Mayank Mamtani | B. Riley Securities, Inc. |